NetworkNewsBreaks – Moleculin Biotech, Inc. (MBRX): Positive FDA Guidance could Allow Earlier Start to Next Clinical Trial
Moleculin Biotech (NASDAQ: MBRX) this morning said it has received verbal positive guidance from the FDA regarding the company’s planned IND submission, which could ultimately enable the company to start its next clinical trial earlier than expected. "This new positive guidance removes a major question mark and allows us to create a tighter timeline for the estimated beginning of our next clinical trial. To be clear, we still can't rule out the possibility of a delay in the timeline, but with the knowledge that the FDA is encouraging us to simply incorporate by reference the prior developer's IND, we believe…







